Director at NewAmsterdam Pharma (NASDAQ: NAMS) gets RSUs, options

Rhea-AI Filing Summary

NewAmsterdam Pharma Co. N.V. director John W. Smither reported equity compensation awards. On January 7, 2026, he received 3,400 restricted stock units (RSUs), each representing one ordinary share, granted for no consideration. All RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.

On the same date, he was also granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share. These option shares will vest on January 2, 2027, the one-year anniversary of the vesting start date, if he continues in service. After these transactions, he directly owns 10,360 ordinary shares and 15,300 options.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Smither John W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	15,300	$0.00	--
Grant/Award	Ordinary Shares	3,400	$0.00	--

Holdings After Transaction: Option (right to buy) — 15,300 shares (Direct); Ordinary Shares — 10,360 shares (Direct)

Footnotes (1)

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Each RSU was granted on January 7, 2026 for no consideration. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smither John W

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/07/2026		A		3,400(1)	A	(2)	10,360	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$35.45	01/07/2026		A		15,300		(3)	01/07/2036	Ordinary Shares	15,300	$0.00	15,300	D

Explanation of Responses:

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

2. Each RSU was granted on January 7, 2026 for no consideration.

3. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

	/s/ Louise Kooij by Power of Attorney from John W. Smither	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NewAmsterdam Pharma (NAMS) report for John W. Smither?

Director John W. Smither reported receiving 3,400 RSUs and an option for 15,300 ordinary shares in NewAmsterdam Pharma Co. N.V. on January 7, 2026.

How many restricted stock units did the NewAmsterdam Pharma (NAMS) director receive and when do they vest?

He received 3,400 RSUs, each equal to one ordinary share. All RSUs will vest on the one-year anniversary of the vesting start date, subject to his continued service.

What stock options were granted to the NewAmsterdam Pharma (NAMS) director and at what exercise price?

He was granted an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share, awarded on January 7, 2026.

When will the stock options granted to the NewAmsterdam Pharma (NAMS) director vest?

All ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, if he continues to serve through that date.

How many NewAmsterdam Pharma (NAMS) shares does John W. Smither own after these grants?

Following the reported transactions, he directly owns 10,360 ordinary shares and holds 15,300 stock options.

Did the NewAmsterdam Pharma (NAMS) director pay anything for the RSUs granted?

No. The filing states that each RSU was granted for no consideration on January 7, 2026.